Drugs / Etrumadenant
Trials 22 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT04892875 | Dec 2023 → Dec 2025 | hypopharynx squamous cell carcinoma, larynx cancer, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Jennifer Choe | Withdrawn | No outcome recorded |
| Phase 1 | NCT05411146 | May → Jul 2022 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05277012 | Feb → Mar 2022 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05154136 | Oct → Dec 2021 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03846310 | Apr 2019 → Nov 2024 | non-small cell lung carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03720678 | Nov 2018 → Jan 2021 | colorectal cancer, gastroesophageal cancer | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03719326 | Oct 2018 → Jul 2021 | ovarian cancer, triple-negative breast carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03629756 | Jul 2018 → Aug 2021 | breast cancer, castration-resistant prostate carcinoma, colorectal cancer, cutaneous neuroendocrine carcinoma +8 | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04660812 | May 2021 → Sep 2025 | colorectal cancer | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04381832 | Jul 2020 → Aug 2024 | castration-resistant prostate carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03555149 | Sep 2018 → Sep 2022 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03193190 | Jul 2017 → Feb 2025 | pancreatic adenocarcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT06048484 | May 2024 → Apr 2027 expected | pancreatic ductal adenocarcinoma | Gulam Manji | Recruiting | No outcome recorded |
| Phase 2 | NCT05915442 | Jul 2023 → Dec 2026 expected | metastatic prostate carcinoma | Catherine Spina | Recruiting | No outcome recorded |
| Phase 2 | NCT05335941 | Jun 2023 → Sep 2027 expected | metastatic malignant neoplasm, urothelial carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05886634 | May 2023 → May 2027 expected | dedifferentiated liposarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05633667 | Mar 2023 → Sep 2029 expected | non-small cell lung carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05024097 | Mar 2022 → Dec 2026 expected | rectal cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 2 | NCT05177770 | Jan 2022 → Apr 2023 | castration-resistant prostate carcinoma | Coherus Oncology, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04791839 | Aug 2021 → Oct 2026 expected | non-small cell lung carcinoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04262856 | May 2020 → Jul 2025 | non-small cell squamous lung carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03821246 | Oct 2019 → Apr 2027 expected | prostate adenocarcinoma | David Oh | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-02 | Gilead Sciences | Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer gilead.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etrumadenant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05154136 ↗ |
| Known as | AB928 | “Etrumadenant (AB928)” NCT05024097 ↗ |
| Action | Inhibit | “Etrumadenant is an A2aR and A2bR antagonist.” NCT03629756 ↗2“Adenosine A2a receptor antagonist” CHEMBL4740383 ↗ “Adenosine A2b receptor antagonist” CHEMBL4740383 ↗ |
| Modality | Small molecule | — CHEMBL4740383 ↗ |
| Route | Oral | “AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle” NCT03193190 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor antagonist” CHEMBL4740383 ↗ |
| Target | ADORA2B | “Adenosine A2b receptor antagonist” CHEMBL4740383 ↗ |